Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
In the last 90 days, Cadrenal Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Cadrenal Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +1 vs. Q1 2025
- Shares held
- 68.4K
- −957 (−1.4%) vs. Q1 2025
- Total value
- $823.9K
- −$398.9K (−32.6%) vs. Q1 2025
- New holders
- 4
- 3 more added
- Sold out
- 3
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CVKD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $379.6K |
| Q1 2026 | 20 | $460.1K |
| Q4 2025 | 20 | $823.9K |
| Q3 2025 | 20 | $1.57M |
| Q2 2025 | 17 | $823.9K |
| Q1 2025 | 16 | $1.22M |
| Q4 2024 | 10 | $215.5K |
| Q3 2024 | 2 | $68 |
| Q2 2024 | 9 | $165.0K |
| Q1 2024 | 10 | $1.04M |
| Q4 2023 | 6 | $407.5K |
| Q3 2023 | 9 | $751.9K |
| Q2 2023 | 3 | $429 |
| Q1 2023 | 3 | $1.34K |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Cadrenal Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 48,595 | $585.6K | 0.00% | +2,962+6.5% | Added |
| Geode Capital Management, LLC | 12,710 | $153.2K | 0.00% | +624+5.2% | Added |
| BlackRock, Inc. | 3,282 | $39.5K | 0.00% | +3,282 | New |
| Raymond James Financial Inc | 1,917 | $23.1K | 0.00% | +1,917 | New |
| Advisor Group Holdings, Inc. | 500 | $6.03K | 0.00% | −1,000−66.7% | Reduced |
| Morgan Stanley | 430 | $5.18K | 0.00% | −700−61.9% | Reduced |
| UBS Group AG | 326 | $3.93K | 0.00% | −8,119−96.1% | Reduced |
| Jones Financial Companies LLLP | 172 | $1.80K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 136 | $1.64K | 0.00% | +136 | New |
| Wells Fargo & Company | 100 | $1.21K | 0.00% | 00.0% | Unchanged |
| Harbour Investments, Inc. | 100 | $1.21K | 0.00% | +100 | New |
| Archer Investment Corp | 35 | $422 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 30 | $362 | 0.00% | 00.0% | Unchanged |
| Farther Finance Advisors, LLC | 25 | $301 | 0.00% | 00.0% | Unchanged |
| Carolina Wealth Advisors, LLC | 20 | $241 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 14 | $169 | 0.00% | +3+27.3% | Added |
| Caldwell Sutter Capital, Inc. | 5 | $60 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| UMA Financial Services, Inc. | 0 | $0 | 0.00% | −52−100.0% | Sold out |
| Frazier Financial Advisors, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |